Inhibrx Enterprise value
What is the Enterprise value of Inhibrx?
The Enterprise value of Inhibrx, Inc. is $1.31B
What is the definition of Enterprise value?
Enterprise value is a measure of a company’s total market value. It is calculated as market capitalization with debt, minority interest, and preferred shares minus total cash and cash equivalents.
ttm (trailing twelve months)
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Enterprise value of companies in the Health Care sector on NASDAQ compared to Inhibrx
What does Inhibrx do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Companies with enterprise value similar to Inhibrx
- Godrej Agrovet has Enterprise value of $1.31B
- Savencia SA has Enterprise value of $1.31B
- Green Plains Inc has Enterprise value of $1.31B
- Network18 Media & Investments has Enterprise value of $1.31B
- Welspun India has Enterprise value of $1.31B
- GIC Housing Finance has Enterprise value of $1.31B
- Inhibrx has Enterprise value of $1.31B
- Magyar Telekom Telecommunications Plc has Enterprise value of $1.31B
- Desktop Metal has Enterprise value of $1.31B
- PTC India has Enterprise value of $1.32B
- Score Media and Gaming has Enterprise value of $1.32B
- Ironwood Pharmaceuticals Inc has Enterprise value of $1.32B
- Social Capital Hedosophia Holdi has Enterprise value of $1.32B